THE JAAGSIEKTE RETROVIRUS: ISOLATION AND COMPARISON WITH A NEW SOUTH AFRICAN LENTIVIRUS NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


THE JAAGSIEKTE RETROVIRUS: ISOLATION AND COMPARISON WITH A NEW SOUTH AFRICAN LENTIVIRUS

Diss Abstr Int [B]; 50(5):1923 1990. Unique Identifier : AIDSLINE ICDB/90660241
York DF; Univ. of Natal, South Africa


Abstract: Jaagsiekte is a contagious cancer affecting the lungs of sheep. Although the etiological agent is Jaagsiekte retrovirus (JSRV), two other retroviruses--viz, South African maedi visna virus (SA OMVV) and a novel Bovine retrovirus (BRV)--have been associated with or implicated in the jaagsiekte disease complex. JSRV was partially purified from lung rinse material, its polypeptide composition was studied by gel electrophoresis and its morphology observed electron microscopically. Monoclonal antibodies were made against purified preparations of the virus and used in the development of JS-specific immunoassays. A cross reaction between JSRV and a polyclonal serum against Mason Pfizer monkey virus (MPMV) was confirmed and used in a Western blot technique to identify, monitor and differentiate JSRV from other viruses. During the study of JSRV another retrovirus, found to be a novel South African isolate of maedi visna virus (SA - OMVV I), was often found in purified JSRV preparations. Being a retrovirus it is also detected by the reverse transcriptase assay which was the only method used to assay and monitor for JSRV during the early stages of our work. Using a Western blot technique and sera against MVV and MPMV it was possible to simultaneously detect and differentiate JSRV from SA - OMVV I. A method was also developed whereby the two viruses could be separated from each other during purification. BRV is a novel virus which originated from bovine cells that had been co-cultivated with white blood cells from an ox suffering from malignant catarrhal fever. Three out of four sheep inoculated with BRV developed JS. A comparative study revealed that BRV was biochemically and morphologically quite different from JSRV. However, serum against MPMV cross-reacted with a 32-kD protein of BRV indicating a serological relationship between JSRV, MPMV and BRV. The possible role of BRV in the etiology of jaagsiekte remains to be elucidated.
Keywords: Animal Antigens, Viral/IMMUNOLOGY Cattle Comparative Study Cross Reactions Malignant Catarrh/MICROBIOLOGY Pulmonary Adenomatosis, Ovine/*MICROBIOLOGY Retroviridae/IMMUNOLOGY/*ISOLATION & PURIF Sheep South Africa SIV/ISOLATION & PURIF Visna-Maedi Virus/ISOLATION & PURIF THESISKWDanimalantigens,viral/immunologycattlecomparativestudycrossreactionsmalignantcatarrh/microbiologypulmonaryadenomatosis,ovine/KWDmicrobiologyretroviridae/immunology/KWDisolation&purifsheepsouthafricasiv/isolation&purifvisna-maedivirus/isolation&purifthesis
900630
M9060639

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .